National Institutes of Health–supported researchers at the University of Pennsylvania and Mayo Clinic reported on 29 January 2026 that a new four-marker blood test could improve early detection of pancreatic ductal adenocarcinoma, according to findings published in Clinical Cancer Research, with the aim of identifying the disease at more treatable stages.
The announcement situates the research within federal cancer programs led by the National Institutes of Health and the National Cancer Institute, highlighting efforts to address one of the lowest survival rates among major cancers through improved screening science and biomarker validation.
NIH-Supported Teams Publish New Blood Test Findings
The National Institutes of Health confirmed that investigators from the University of Pennsylvania Perelman School of Medicine and the Mayo Clinic conducted the study using banked blood samples from patients with and without pancreatic cancer. Meanwhile, the results were formally published in the peer-reviewed journal Clinical Cancer Research, providing an official scientific record for the reported performance of the test.
According to the NIH announcement, the researchers used a phased validation approach to compare known and novel biomarkers in plasma samples. Additionally, the National Cancer Institute noted that the work aligns with federal priorities to advance early detection tools that can be evaluated in larger clinical populations.
| Indicator | Recent Movement | Context |
|---|---|---|
| Publication Date | January 2026 | Clinical Cancer Research published the NIH-supported study detailing the four-marker blood panel performance. |
| Institutions Involved | Two research centers | University of Pennsylvania Perelman School of Medicine and Mayo Clinic led the biomarker analysis, according to NIH. |
| Funding Source | Federal research grants | NIH and National Cancer Institute grants supported the study, as listed in the publication acknowledgements. |
Biomarker Performance and Accuracy Results Table
The NIH reported that the four-marker panel combined two established markers, CA19-9 and THBS2, with two newly identified proteins, aminopeptidase N and polymeric immunoglobin receptor.
Meanwhile, the published data showed that the panel distinguished pancreatic cancer cases from non-cases at a reported accuracy of 91.9 percent across all stages at a five percent false positive rate.
According to the National Cancer Institute summary of the findings, the test identified 87.5 percent of early-stage cases in the study cohort. Additionally, the agencies noted that these figures were generated from retrospective sample analysis, which informs but does not replace prospective screening trials.
Pancreatic Cancer Detection and Survival Context
The National Cancer Institute states that pancreatic cancer remains one of the most lethal malignancies, with approximately one in ten patients surviving five years after diagnosis. However, the NCI also reports that earlier-stage detection is associated with improved treatment outcomes and broader therapeutic options.
According to the Centers for Disease Control and Prevention’s cancer surveillance summaries, there is currently no routine population-wide screening test for pancreatic cancer. Meanwhile, federal health agencies frame biomarker research as a pathway to reduce late-stage diagnoses that often limit clinical intervention.
Stakeholder Comments
Kenneth Zaret, Ph.D., Lead Investigator, University of Pennsylvania Perelman School of Medicine, said;
“By adding ANPEP and PIGR to the existing markers, we’ve significantly improved our ability to detect this cancer when it’s most treatable.”
Kenneth Zaret, Ph.D., added;
“Our retrospective study findings warrant further testing in larger populations, particularly in people before they show symptoms.”
Development of the Four-Marker Panel
The NIH described how researchers evaluated existing biomarkers, including CA19-9 and THBS2, which are already used in clinical monitoring but have limitations as screening tools.
According to the agency, CA19-9 can be elevated in benign conditions such as pancreatitis and bile duct obstruction, while some individuals do not produce the marker due to genetic factors.
Meanwhile, the study team identified aminopeptidase N and polymeric immunoglobin receptor as proteins that were elevated in early-stage pancreatic cancer samples.
The National Cancer Institute stated that combining these markers improved the panel’s ability to distinguish cancer patients from both healthy individuals and those with non-cancerous pancreatic conditions.
Future Screening Potential and Research Pathway
The NIH reported that the research team plans to pursue larger prediagnostic studies to determine whether the test can be applied to high-risk populations, including individuals with family histories or genetic risk factors.
Additionally, the National Cancer Institute noted that such trials are designed to evaluate how biomarker panels perform in real-world clinical screening environments.
According to federal research guidance, results from expanded studies will inform whether the test can progress toward regulatory evaluation and potential clinical adoption. Meanwhile, health agencies emphasized that continued grant-supported research remains necessary before the panel can be considered for routine use.
In Conclusion
The NIH-supported study positions the four-marker blood panel as a research advance aimed at improving early detection of pancreatic ductal adenocarcinoma through federally funded biomarker science. By publishing performance data in a peer-reviewed journal, the research establishes a reference point for future clinical validation and screening trials.
Federal health agencies indicated that continued evaluation in larger populations will determine whether the test can move beyond retrospective analysis toward broader clinical application.
Sources: National Institutes of Health, National Cancer Institute, and Clinical Cancer Research.
Prepared by Ivan Alexander Golden, Founder of THX News, an independent news organization delivering timely insights from global official sources.
Combines AI-analyzed research with human-edited accuracy and context.
